StudyFinder



Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Angelica Herbal Supplement AGN-Cognl.Q Acute Dose Safety and Pharmacokinetics (PK) Dose-Response in Prostate Cancer Patients (PK Dose Trial)

The primary objective is to estimate the maximum tolerated dose of AGN-Cognl.Q. Subjects (total sample size n = 12 evaluable subjects), each for 4 ascending AGN-Cognl.Q dose levels in the form of AGN-Cognl.Q capsules (up to 10 capsules per dose), for single-dose safety metrics with a 1-week washout between doses.

Consented patients will be screened for physical exam and lab tests, and vital signs to establish eligibility (Visit 1, screening visit). The subjects will need to come into the research clinic in Hershey Medical Center on a weekly basis to take a single dose of AGN-CognI.Q by mouth in the morning for a series of blood draw over the span of the next 24 h to measure the amount of AGN Cognl.Q in their body. The total number of times the subjects will visit the clinic is 8 including a Screening visit (Visit 1) and an End of Treatment visit (Visit 8).

Monika Joshi
Kathleen Rizzo - at krizzo@pennstatehealth.psu.edu
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05375539
STUDY00020512
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Willingness and ability to given informed consent
agree to comply with all study procedures and attend all study visits to the best of their ability
male with age >= 40 years
Histologically confirmed prostate cancer diagnosis in the past
Not on concurrent androgen deprivation therapy

Exclusion Criteria:
Subjects with metastatic cancer as determined by chest and abdominal CT scan, PET/CT, MRI, bone scan within the past 12 months
Subjects who are receiving chemotherapy, or oral TKI, or immunotherapy
Subjects who are receiving any other investigational agents
Uncontrolled intercurrent illness that would limit compliance with study requirements
Subjects currently taking herbal supplements containing AGN extract, including Cognl.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,